COMMUNIQUÉS West-GlobeNewswire

European Commission grants marketing authorisation for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease
25/09/2026
Approval is based on NEXUS data and follows positive CHMP opinion in July; first European launch is expected by end of 2026 BARCELONA, Spain and DÜSSELDORF, Germany, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Neuraxpharm Group [...]
Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior
25/09/2026
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 25, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company developing novel small molecule allosteric [...]
IBA va coordonner LIFEDESTINY, un nouveau projet européen pour l'élimination durable des PFAS
25/09/2026
Louvain ‑ la ‑ Neuve, Belgique, le 25 septembre 2026, 7h00 – IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélérateurs de particules, annonce ce jour qu'elle coordonnera LIFEDESTINY [...]
IBA to coordinate LIFEDESTINY, a new European LIFE project to advance sustainable PFAS remediation
25/09/2026
Louvain-la-Neuve, Belgium, 25 September 2026, 7 a.m. CEST – IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, today announces it will coordinate the LIFEDESTINY, a new [...]
CROSSJECT publie ses résultats du premier semestre 2026 et présente une structure financière profondément renforcée
25/09/2026
CROSSJECT publie ses résultats du premier semestre 2026 et présente une structure financière profondément renforcée Trésorerie de 12,3 M€ au 30 juin 2026, multipliée par 2,4 par rapport au 31 décembre 2025 (5,1 M€), [...]
CROSSJECT Reports Its First-Half 2026 Results and Presents a Significantly Strengthened Financial Structure
25/09/2026
Cash and cash equivalents of €12.3 million as of June 30, 2026, a 2.4-fold increase compared to December 31, 2025 (€5.1 million), following the €15 million capital increase completed in May. Shareholders’ equity [...]
CROSSJECT structure sa gouvernance pour la phase de déploiement industriel et commercial
25/09/2026
Le Directoire est élargi à cinq membres : Olivier LACOMBE, Didier MORIN et Lionel SELTZ rejoignent Patrick ALEXANDRE et Isabelle LIEBSCHUTZ Une direction qui couvre l’intégralité de la chaîne de valeur : développement [...]
CROSSJECT strengthens its governance for the industrial and commercial deployment phase
25/09/2026
The Executive Board is expanded to five members: Olivier Lacombe, Didier Morin and Lionel Seltz join Patrick Alexandre and Isabelle Liebschutz A leadership team covering the entire value chain: pharmaceutical [...]
Avacta Group plc: The FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic Cancer
25/09/2026
LONDON and PHILADELPHIA, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, the "Company", "Avacta"), a life sciences company developing innovative, targeted oncology drugs, today announces the [...]
Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment
25/09/2026
Blood biomarkers associated with amyloid clearance differ from those associated with cognitive decline in patients receiving lecanemab FREMONT, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq [...]
ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering
25/09/2026
SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today the pricing of its upsized [...]
Eurobio Scientific: COMMUNIQUÉ DU 24 SEPTEMBRE 2026 RELATIF AU DEPÔT D’UNE OFFRE PUBLIQUE DE RETRAIT SUIVIE D’UN RETRAIT OBLIGATOIRE VISANT LES ACTIONS DE LA SOCIÉTÉ
24/09/2026
COMMUNIQUÉ DU 24 SEPTEMBRE 2026 RELATIF AU DEPÔT D’UNE OFFRE PUBLIQUE DE RETRAIT SUIVIE D’UN RETRAIT OBLIGATOIRE VISANT LES ACTIONS DE LA SOCIÉTÉ INITIEE PAR EB DEVELOPMENT PRESENTEE PAR CIC BANQUE PRESENTATRICE ET [...]
Grant of Restricted Stock Units and Warrants to Employees in Genmab
24/09/2026
Company Announcement COPENHAGEN, Denmark; September 24, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 13,794 restricted stock units and 13,331 warrants to employees of the [...]
Embark Behavioral Health Releases 2025 Outcomes Report Highlighting Measurable Improvements for Youth Mental Health
24/09/2026
Embark’s new data from more than 3,000 admissions in 2025 shows meaningful reductions in depression, anxiety and distress, along with gains in overall well-being, based on validated clinical assessments completed [...]
PROLLENIUM® Spotlights the Future of Regenerative Aesthetics at Aesthetic Next 8.0 and Chateau Prollenium Dallas
24/09/2026
RICHMOND HILL, Ontario, Sept. 24, 2026 (GLOBE NEWSWIRE) -- PROLLENIUM ® , a global leader in aesthetic innovation, brought clinical education, regenerative aesthetics and injectable technique to Dallas through two [...]
Healthcare’s Challenges Have Changed. MGMA’s Purpose Has Not.
24/09/2026
MGMA celebrates 100 years of helping medical practice leaders turn shared challenges into practical solutions Englewood, Colorado and San Antonio, Texas, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Workforce shortages. Financial [...]
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency
24/09/2026
-- Clearance highlights continued execution, modularity and momentum across Prime Medicine’s liver franchise, building on recent regulatory clearances for PM577a -- -- Initial clinical data expected in 2027 -- CAMBRIDGE [...]
Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert
24/09/2026
Keli Walbert brings two decades of commercial leadership and proven track record of successful launches to the Board CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics ( [...]
Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update
24/09/2026
REDWOOD CITY, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare rare disease company focused on treating refractory hypoglycemia caused by [...]

Pages